Filing Flows › Jazz Pharmaceuticals (JAZZ) › Q2 2025
Jazz Pharmaceuticals (JAZZ) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.0B for the second quarter 2025 (Q2 2025), +2% from a year earlier and +16% from the quarter before. Operating margin was -65.6%, net loss $718M (68.7% of revenue).
Jazz Pharmaceuticals, Q2 2025: revenue $1.0B (+2% year over year), operating margin -65.6%, net loss $718M, operating cash flow $88.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0B | +16% | +2% |
| Operating profit | −$686M | — | — |
| Net earnings | −$718M | — | — |
| Operating cash flow | $88.8M | -79% | -73% |
| Free cash flow | $75.9M | -82% | -77% |
What changed
Revenue was $1.0B in Q2 2025, up 2% year over year and up 16% from the previous quarter. Xywav was the largest line at 40% of revenue. Xywav added $0.05B year over year (up 13%), 214% of the total change. Xyrem declined 43%.
Operating costs exceeded revenue by $0.69B, an operating margin of -65.6%. Total costs grew 110% against revenue growth of 2%. The fastest-growing cost line was Other operating costs (+347%). The quarter ended with a net loss of $0.72B, wider than the previous quarter's $0.09B loss.
Operating cash flow was $0.09B (down 73% year over year). Non-cash charges added back $0.17B of depreciation and amortization and $0.06B of share-based compensation. Working capital and other items added $0.57B. Capital expenditures of $0.01B left free cash flow of $0.08B.
Questions
What was Jazz Pharmaceuticals' revenue in the second quarter 2025?
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.0B for the second quarter 2025 (Q2 2025), +2% from a year earlier and +16% from the quarter before.
Was Jazz Pharmaceuticals profitable in the second quarter 2025?
Operating loss was $686M (-65.6% of revenue) and net loss $718M.